Business
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldw
About this update from Anteris Technologies Global Corp.
[{"type":"image","alt":"Anteris Technologies Global Corp.","displaySize":"","headline":null,"caption":"Anteris Technologies Global Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":83,"url":"https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8tNysNEA0DQBTcTu5RQZLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebb91cde24fc8bfaa2bbd449d64df87a","width":300,"height":83}},"lazy":false},{"type":"text","content":"MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis.","length":627,"tagName":"p"},{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Over 100 patients successfully treated with the DurAVR® THV, including de novo (first time) aortic stenosis cases, valve-in-valve (ViV) patients and complex anatomies such as bicuspid aortic valve patients*","length":206,"tagName":"p"}]},{"val":[{"type":"text","content":"65 patients have successfully completed the primary endpoint measures of safety and efficacy, including hemodynamic benefit at 30-days post implant","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"One-year efficacy data on 37 aortic stenosis patients continues to validate the exceptional hemodynamic performance, with sustained large effective orifice areas (EOAs) and low mean pressure gradients (MPGs)","length":207,"tagName":"p"}]},{"val":[{"type":"text","content":"Excellent safety profile demonstrated at one-year, with no valve or cardiovascular related mortality","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Range of valve sizes used to accommodate a broad patient population","length":67,"tagName":"p"}]}],"tagName":...